Short-term Metabolic Effects of Mirtazapine in Healthy Subjects


The purpose of this study is to determine metabolic changes upon a 7 day medication of 30 mg mirtazapine per day in healthy subjects.

Full Title of Study: “Phase 1 Study of Mirtazapine in Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2010


  • Drug: mirtazapine
    • 30 mg mirtazapine once daily for 7 days

Arms, Groups and Cohorts

  • Experimental: mirtazapine

Clinical Trial Outcome Measures

Primary Measures

  • Metabolic changes upon a 7 day medication of 30 mg mirtazapine per day
    • Time Frame: 3 days

Participating in This Clinical Trial

Inclusion Criteria

  • Male sex
  • Age 20-25 years
  • Somatically and mentally healthy
  • Normal body weight (body mass index (BMI)18.5-25)

Exclusion Criteria

  • Smoking within the last 6 months
  • Medication within last 6 months
  • Current or former psychiatric illness
  • Positive family history (first grade relatives) for metabolic diseases
  • Alcohol abuse
  • Current or former illicit drug abuse
  • Current or former drug abuse
  • Known intolerance to, or former prescription of study medication
  • Participation in other clinical trials at the same time or participation in clinical trials associated with administration of a drug within the last 6 months
  • Homelessness
  • Shift work within last 12 months
  • Known hypersensitivity to mirtazapine or other components of the drug given
  • Known epilepsy; glaucoma; liver, kidney, or heart disease; urinary dysfunction; hypotonia; diabetes or any other metabolic disease
  • Known hematologic disease, especially agranulocytosis or leukopenia
  • Blood donation within last 6 months prior to the begin of the study
  • Hemoglobin below 13.5 mg/dL

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 25 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Max-Planck-Institute of Psychiatry
  • Provider of Information About this Clinical Study
    • Prof. Florian Holsboer, Max-Planck-Institute of Psychiatry
  • Overall Official(s)
    • Florian Holsboer, MD, PhD, Principal Investigator, Max Planck Institute of Psychiatry, Munich

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.